Xeris Biopharma Holdings, Inc. (XERS) intrinsic value & 10-year financials
Xeris Biopharma Holdings, Inc. (XERS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 70.7% a year to $291.8M, with an average return on invested capital of -53.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.31
- Market cap
- $1.8B
- Revenue (FY2025)
- $291.8M
- Revenue growth (7-yr CAGR)
- 70.7%
- ROIC (10-yr avg)
- -53.5%
- Free cash flow (FY2025)
- —
XERS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $291.8M | $554.0K | $0.00 | — | 8.5% | 15.6% |
| FY2024 | $203.1M | -$54.8M | -$0.37 | — | -16.6% | -20.5% |
| FY2023 | $163.9M | -$62.3M | -$0.45 | — | -26.8% | -31.8% |
| FY2022 | $110.2M | -$94.7M | -$0.70 | — | -74.3% | -68.5% |
| FY2021 | $49.3M | -$122.7M | -$1.55 | -$96.6M | -233.7% | -115.6% |
| FY2020 | $20.2M | -$91.1M | — | -$80.9M | -414.5% | -100.3% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Xeris Biopharma Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Xeris Biopharma Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -53.5% ROIC.
Xeris Biopharma Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Xeris Biopharma Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.